Quantcast

Industry news that matters to you.  Learn more

Columbia University Medical Center Sponsors Clinical Study Using Biocept’s Liquid Biopsy Platform to Evaluate Cerebrospinal Fluid of Breast Cancer Patients for Metastatic Biomarkers

Biocept, Inc., a leading commercial provider of clinically actionable liquid biopsy tests designed to improve the outcomes of cancer patients, announces that Columbia University Medical Center will conduct a study to evaluate the clinical utility of the Company’s Target Selector™ platform to diagnose leptomeningeal metastases (LM) in patients with breast cancer.  LM occurs when tumor cells gain access to cerebrospinal fluid (CSF) pathways and regrow in distant sites within the spinal cord and brain leading to neurological complications. Biocept’s liquid biopsy platform will be used to test the CSF of breast cancer patients and will be compared to standard methods for confirming the diagnosis of LM.

Biocept to Collaborate on Biopharma Company Clinical Trial by Identifying Biomarkers Found in Cerebral Spinal Fluid for Patients with Lung Cancer that has Spread to the Brain

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces a collaboration on a biopharmaceutical company clinical trial analyzing biomarkers using both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from cerebrospinal fluid (CSF). The trial is being conducted in patients with non-small cell lung cancer (NSCLC) whose disease has spread to the brain or membranes surrounding the brain and spinal cord, known as leptomeningeal disease.

Biocept Secures Agreements with Preferred Provider Organizations Fortified Provider Network and Three Rivers Provider Network

Biocept, Inc., a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of patients with cancer, announces two new agreements with preferred provider organization (PPO) networks.  Fortified Provider Network and Three Rivers Provider Network members now have network access to Biocept’s proprietary non-invasive liquid biopsy testing.  These new agreements cover 26 million members, bringing the total number of consumers with access to Biocept’s blood-based liquid biopsy testing through their healthcare plans to approximately 133 million. 

Biocept to Present at LD Micro Main Event

Biocept, Inc., a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of patients with cancer, announces that President and CEO Michael Nall is scheduled to present a corporate overview at the LD Micro Main Event onThursday, December 3, 2015 at 12:00 p.m. Pacific time.  The conference is being held at Luxe Sunset Boulevard Hotel in Los Angeles.

Lung Cancer Study Demonstrates Extremely High Sensitivity of Biocept’s Blood-Based Liquid Biopsy Platform in Detecting EGFR Mutation in Plasma with 93% Concordance with Tissue Biopsy

Biocept, Inc., a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of cancer, today announced that findings demonstrating the ability to reliably detect actionable genetic alterations used in the diagnosis, monitoring and treatment of patients with lung cancer using its blood based biopsy, instead of surgical biopsy, will be presented Friday, November 6th, at the Association for Molecular Pathology Annual (AMP) Meeting in Austin, Texas.